SCHEMBL19106909

SCHEMBL19106909

CC(C)c1cccc(-n2ncnn2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 6/20 0.41
GRIN1 Q05586 6/20 0.41
GRIN2B Q13224 6/20 0.41
NOTUM Q6P988 4/20 0.39
ESRRA P11474 1/20 0.38
NPBWR1 P48145 1/20 0.37
MCHR1 Q99705 1/20 0.37
HDAC4 P56524 2/20 0.36
HDAC8 Q9BY41 2/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MDM4 O15151 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
TP53 P04637 1/20 0.36
CYP3A4 P08684 1/20 0.36
MAPT P10636 1/20 0.36
TYR P14679 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15686706 0.80 RXRA (0.43) RXRAGRIN1GRIN2BNOTUMESRRA
SCHEMBL19106908 0.78 NOTUM (0.50) NOTUMESRRAALDH1A1MAPTTDP1
SCHEMBL7994256 0.73 NOTUM (0.42) RXRAGRIN1GRIN2BNOTUMESRRA
SCHEMBL8470236 0.73 PDPK1 (0.35)
SCHEMBL9272142 0.73 MEN1 (0.42) ALDH1A1CA2CYP3A4CA5ASMN1; SMN2
SCHEMBL8230259 0.73 NOTUM (0.51) NOTUMKDM4EALDH1A1TP53CYP3A4
SCHEMBL7994431 0.71 NOTUM (0.65) RXRAGRIN1GRIN2BNOTUMALDH1A1
SCHEMBL15362397 0.71 NOTUM (0.65) RXRAGRIN1GRIN2BNOTUMESRRA
SCHEMBL2211763 0.71 KDM4E (0.46) NOTUMHPGDKDM4EALDH1A1MAPT
SCHEMBL19836609 0.70 RXRA (0.42) RXRAGRIN1GRIN2BNOTUMESRRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9926317-B2 Inhibitors of the renal outer medullary potassium channel MERCK SHARP DOHME CORP. (US) 2018-03-27 US disclosed
US-20170197964-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME LLC 2017-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197964-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL KCNJ11, KCNJ1, KCNJ2 RXRA 4120/4885GRIN1 547/4885GRIN2B 1121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.